Akebia Therapeutics Inc
SWB:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
SWB:AX9
|
US |
|
M
|
MorphoSys AG
XBER:MOR
|
DE |
|
TechnoPro Holdings Inc
F:30T
|
JP |
|
G
|
Goliath Resources Ltd
OTC:GOTRF
|
CA |
|
Blackstone Secured Lending Fund
F:GM8
|
US |
|
Agree Realty Corp
NYSE:ADC
|
US |
|
G
|
Golden Ocean Group Ltd
F:KT31
|
BM |
|
M
|
Myer Holdings Ltd
SWB:30M
|
AU |
Wall St Price Targets
AX9 Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AX9 is 3.58 EUR with a low forecast of 2.53 EUR and a high forecast of 5.27 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AX9's stock price target?
Price Target
3.58
EUR
According to Wall Street analysts, the average 1-year price target for AX9 is 3.58 EUR with a low forecast of 2.53 EUR and a high forecast of 5.27 EUR.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
9%
The compound annual growth rate for Revenue over the next 8 years is 9%.
What is the Gross Profit forecast for Akebia Therapeutics Inc?
Projected CAGR
-1%
The compound annual growth rate for Gross Profit over the next 3 years is -1%.
What is the Operating Income forecast for Akebia Therapeutics Inc?
Projected CAGR
34%
The compound annual growth rate for Operating Income over the next 8 years is 34%.
